HIV Infections
Conditions
Keywords
Thymopentin, Acquired Immunodeficiency Syndrome
Brief summary
Examine the ability of thymopentin (Timunox) to: Reduce the amount and/or frequency of virus isolation. Stimulate the immune system and alter the clinical findings in patients infected with HIV who do not yet have AIDS.
Interventions
DRUGThymopentin
Sponsors
Immunobiology Research Institute
Study design
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Concurrent Medication: Allowed: * Aerosolized pentamidine. Prior Medication: Allowed: * Aerosolized pentamidine.
Exclusion criteria
Co-existing Condition: Patients with an abnormal chest x-ray indicative of active disease (opportunistic infection) within 30 days prior to entry are excluded. Concurrent Medication: Excluded within 90 days of study entry: * Zidovudine (AZT). Prior Medication: Excluded within 30 days of study entry: * Immunomodulatory or experimental therapy. * Excluded within 90 days of study entry: * Zidovudine (AZT). Patients must not have: * Hemophilia A or B or other hematologic disorders requiring current or previous administration of blood products. * AIDS as defined by the CDC (except for those with HIV wasting syndrome). * Significant hepatic disease. * Thrombocytopenia (\< 75000 platelets/mm3). Patient must voluntarily sign consent and be seropositive for HIV-1 (ELISA assay) confirmed by Western blot. * HIV-1 p24 antigen must be detected in supernatant fluids from co-cultures of patient's peripheral blood monocytes (PBMC) on two separate occasions. * Patients with HIV wasting syndrome are included. Intravenous drug abuse.
Countries
United States
Outcome results
None listed